Company Overview of Chiasma (Israel) ltd.
Chiasma (Israel) ltd., a biopharmaceutical company, develops oral drugs based on transient permeability enhancer system. The company offers oral octreotide acetate for the treatment of acromegaly. Its pipeline products include novel drugs which addresses unmet needs for well-defined markets. The company focuses primarily on orphan indications. The company was founded in 2001 and is based in Jerusalem, Israel. Chiasma (Israel) ltd. operates as a subsidiary of Chiasma, Inc.
10 Hartom Street
Founded in 2001
Key Executives for Chiasma (Israel) ltd.
Chief Executive Officer and Director
Vice President of Finance and Administration
Vice President of BD and Commercial Planning
Vice President of Quality Assurance & Regulatory Affairs
Compensation as of Fiscal Year 2014.
Chiasma (Israel) ltd. Key Developments
Roche AG Cancels $600 Million Chiasma Deal
Aug 6 14
Roche AG has notified Israeli startup Chiasma that it has cancelled a commercial agreement for a product for treatment of acromegaly (gigantism). The agreement, signed in February 2013, would have generated $600 million for Chiasma's investors, had it been fully implemented. Due to its premature cancelation, Chiasma's revenue from the deal to date totaled only a $65 million advance and several more tens of millions of dollars as payments for milestones.
Roche and Chiasma Announce Collaboration to Develop and Commercialize Chiasma's Octreolin(R) for acromegaly and neuroendocrine tumors
Feb 18 13
Roche and Chiasma announced that they have entered into an agreement to develop and commercialize Chiasma's proprietary product Octreolin, initially for acromegaly and subsequently for neuroendocrine tumors. Octreolin is an investigational oral form of the peptide octreotide, a somatostatin analog that is commercially available only by injection. Octreolin is currently in a pivotal phase 3 clinical trial for acromegaly. Under the terms of the agreement, Roche received a worldwide exclusive license to Octreolin, and will assume responsibility for the commercialization of Octreolin. Genentech will market the product in the United States after US FDA approval. Chiasma will continue development through completion of the pivotal phase 3 clinical trial for acromegaly. The arrangement includes an upfront payment to Chiasma of $65 million, future considerations of up to $530 million in development and commercial milestones, as well as tiered, double-digit royalties on Octreolin net sales. Evercore Partners served as Chiasma's financial advisor on the transaction, and Latham & Watkins LLP served as its legal counsel.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries